Skip to main content
Caplight Logo









Antegenes

Antegenes

Private
TartuHealthcare & Life Scienceshttps://antegenes.com/

Last Round

Grant

Aug 2, 2022

Total Funding Raised

$2.91M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Antegenes is a health technology company that develops and provides polygenic risk score-based genetic tests for the personalized prevention and early detection of common cancers.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics

Business Model

B2B2C

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

polygenic risk scorePRSgenetic testingprecision medicineclinical decision supportgenetic risk assessmentpreventive screeninggenomicspersonalized medicinepredictive healthDNA testinghealth techcancer screeninggenetic counselingIVD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Antegenes Comparables

Compare Antegenes with similar companies based on industry and business-model similarity.

Antegenes comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GENinCode PLC
81%
Allelica, Inc.
80%
Genetic Technologies Limited
76%

Antegenes Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 2, 2022
GrantAug 2, 2022
SeedAug 2, 2022
SeedNov 9, 2021

Key People

Founding team and executive leadership

Jagnar Pindmaa

Chief Technology Officer

Executive Team

Anna Padrik

Acting COO

Executive Team

Berit Kolk

Chief Operating Officer

Executive Team

Akshay Mody

Chief Medical Officer General Manager UK, Non Executive Board Member

Executive Team

Antegenes Investors

Notable investors and investment history

Antegenes investors
InvestorRounds
EIT HealthGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 45% MoM, reaching 1.1K.

  • May 19, 2026

    Monthly visitors increased 53% MoM.

Antegenes Filings

Explore SEC and related filing metadata, where available.

Antegenes filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Antegenes's valuation, stock price, and market status.

Is Antegenes a public or private company?

Antegenes is a private company.

What is the current stock price of Antegenes?

Antegenes is a private company with no public stock price. No recent secondary market data is available.

How much is Antegenes worth (valuation)?

Valuation information for Antegenes is not publicly available.

Can I buy Antegenes stock?

Antegenes shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Antegenes's last funding round?

Antegenes's most recent funding round was Grant on August 2, 2022.

Who are the main investors in Antegenes?

Key investors in Antegenes include EIT Health.

Will Antegenes IPO soon?

No public IPO plans have been announced for Antegenes.

How can I track Antegenes secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Antegenes's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTartu
Employee Range11
Year Founded2018
Last FundingAug 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?